SNC
LXRX icon

Stifel Nicolaus & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

Stifel Nicolaus & Co’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$283K Sell
16,991
-8,473
-33% -$142K ﹤0.01% 1184
2013
Q2 		$387K Buy
+25,464
New +$387K 0.01% 964

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Stifel Nicolaus & Co's LXRX Position: Q3 2013 in Review

Stifel Nicolaus & Co reduced its Lexicon Pharmaceuticals (LXRX) stake by 33% in Q3 2013, selling an estimated $142K and leaving 16,991 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Stifel Nicolaus & Co first reported a position in LXRX in Q2 2013 and has held it in 2 quarters since. The position peaked at $387K in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

  • Stifel Nicolaus & Co held 16,991 shares of Lexicon Pharmaceuticals worth $283K as of Q3 2013.
  • Stifel Nicolaus & Co sold 8,473 Lexicon Pharmaceuticals shares in Q3 2013, an estimated $142K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1184 holding.
  • Stifel Nicolaus & Co first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • Stifel Nicolaus & Co's Lexicon Pharmaceuticals position peaked at $387K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.